Featured Research

from universities, journals, and other organizations

Single Enzyme Necessary For Normal Brain, Vertebrae, Urogenital Tract And Lower Body Development In Mammals

Date:
January 17, 2001
Source:
Cold Spring Harbor Laboratory
Summary:
Two independent research teams have discovered that a single enzyme is necessary for normal brain, vertebrae, urogenital tract and lower body embryological development in mammals. Dr. Hiroshi Hamada of Japan, Dr. Martin Petkovich of Canada, and their colleagues report in jointly published papers that the enzyme CPY26 metabolizes retinoic acid, an essential derivative of vitamin A. Retinoic acid (RA) regulates development by activating the expression of specific target genes throughout the embryo. The formation of an uneven distribution of RA along the central body axis of the developing embryo is essential for normal development.

Two independent research teams have discovered that a single enzyme is necessary for normal brain, vertebrae, urogenital tract and lower body embryological development in mammals. Dr. Hiroshi Hamada of Japan, Dr. Martin Petkovich of Canada, and their colleagues report in jointly published papers that the enzyme CPY26 metabolizes retinoic acid, an essential derivative of vitamin A. Retinoic acid (RA) regulates development by activating the expression of specific target genes throughout the embryo. The formation of an uneven distribution of RA along the central body axis of the developing embryo is essential for normal development. By discovering that CPY26 degrades RA, and thereby establishes this uneven distribution of RA, scientists have determined that CPY26 plays a pivotal role in maintaining the fidelity of the mammalian embryo.

It has been known since the 1930s that vitamin A is necessary for normal embryological development. Since animal cells cannot make RA de novo, they must obtain it from dietary sources of vitamin A. Too little or too much vitamin A intake during pregnancy results in a host of characteristic morphological defects, including cranio-facial, cardiac, lung, genito-urinary and neurological abnormalities. Thus, there are stringent guidelines governing vitamin A consumption during pregnancy. The level of RA in the embryo is maintained by a delicate balance between RA synthesis and RA degredation. The effectiveness of RA as a developmental regulator depends on the precise control of its distribution.

In order to elucidate the developmental role of CPY26, Dr. Hamada, Dr. Petkovich and colleagues removed the gene Cpy26 from a srain of mice. Cpy26 mutant mouse embryos exhibited elevated levels of RA in those areas that normally express CPY26. This data established that CPY26 acts to metabolically degrade RA in vivo. The Cpy26 mutant mouse embryos were not viable; they exhibited major defects including spina bifida, truncation of the posterior body, kidney, brain and vertebrae abnormalities. The most severe developmental defect resulting from the loss of CPY26 activity was complete hindlimb fusion, resulting in a ‘mermaid tail’. Since the CPY26 knock-out mice phenotypes closely resembled those resulting from excess RA, this suggested further that CPY26 functions normally to maintain specific areas of the developing embryo in an RA depleted state.

Dr. Hamada, Dr. Petkovich and colleagues have demonstrated that CPY26 acts to protect the developing mammalian embryo from the deleterious effects of excessive RA activity. The discovery that CPY26 functions to restrict the field of RA signaling represents a significant advance in our understanding of the role and pattern of retinoic acid activity in the developing embryo. Further work to delineate the pathway of CPY26 action will lend insight into the molecular mechanisms of RA-associated congenital defects like spina bifida, fetal vitamin A deficiency syndrome and caudal regression syndrome.


Story Source:

The above story is based on materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Cold Spring Harbor Laboratory. "Single Enzyme Necessary For Normal Brain, Vertebrae, Urogenital Tract And Lower Body Development In Mammals." ScienceDaily. ScienceDaily, 17 January 2001. <www.sciencedaily.com/releases/2001/01/010116080119.htm>.
Cold Spring Harbor Laboratory. (2001, January 17). Single Enzyme Necessary For Normal Brain, Vertebrae, Urogenital Tract And Lower Body Development In Mammals. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/01/010116080119.htm
Cold Spring Harbor Laboratory. "Single Enzyme Necessary For Normal Brain, Vertebrae, Urogenital Tract And Lower Body Development In Mammals." ScienceDaily. www.sciencedaily.com/releases/2001/01/010116080119.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins